Welcome to our dedicated page for PRF Technologies news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PRF Technologies stock.
PRF Technologies Ltd. reports developments across clinical-stage specialty pharmaceuticals and AI-driven solar analytics. The company focuses on reformulating established therapeutics for post-operative pain management and, through majority-owned LayerBio, is developing OcuRing™-K, a bio-erodible intraocular ring designed to deliver ketorolac for post-cataract pain and inflammation.
PRF news also covers the company’s DeepSolar business unit, which develops AI-driven digital asset management, forecasting, performance monitoring, and technical due diligence tools for utility-scale solar plants. Recurring updates include ocular drug-delivery regulatory milestones, preclinical and clinical safety data, patent activity, SaaS deployments, commercial collaborations, capital actions, and governance changes.
PainReform (Nasdaq: PRFX) announced successful batch manufacturing of PRF-110 and progress towards Phase 3 clinical trials expected in H2 2022. CEO Ilan Hadar confirmed that FDA approval for the 505(b)(2) pathway sets the stage for efficient trial execution. The company has $15.4 million in cash and no debt, ensuring capital availability for key milestones. Q1 2022 reported R&D expenses decreased to $680,000, and net loss decreased to $1.694 million, reflecting cost management. PainReform focuses on reformulating established therapeutics for enhanced surgical pain relief.
PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, announced that CEO Ilan Hadar will present at the Noble Capital Markets’ Eighteenth Annual Investor Conference on April 20-21, 2022, in Hollywood, Florida. Hadar's presentation is scheduled for April 20 at 12:00 pm ET in Seminole Ballroom C, with a breakout session at 4:00 pm ET at Table 9. A video webcast of the presentation will be available the following day on the Company's website and other platforms, archived for 90 days.
PainReform Ltd. (Nasdaq: PRFX) announced its participation in the 2022 Virtual Growth Conference hosted by Maxim Group LLC and M-Vest, scheduled for March 28-30, 2022, from 9:00 a.m. to 5:00 p.m. EDT. The conference will include various discussions and presentations, featuring a corporate update by CEO Ilan Hadar. To attend, individuals must register as M-Vest members. PainReform focuses on reformulating established therapeutics, with its lead product PRF-110 aimed at providing extended post-operative pain relief through a unique drug-delivery system.
PainReform Ltd. (Nasdaq: PRFX) provided a business update for 2021, revealing plans to start a Phase 3 trial of PRF-110 for bunionectomy in H2 2022. The company has $16.6 million in cash, a positive working capital of $18.3 million, and no debt. R&D expenses surged to $2.9 million from $0.4 million in 2020, while the net loss increased to $7.2 million. PainReform's lead product, PRF-110, aims to meet the $35 billion post-operative pain management market, potentially reducing opioid use. Key developments are anticipated in 2022 to enhance shareholder value.
TEL AVIV, Israel, Dec. 14, 2021 – PainReform Ltd. (Nasdaq: PRFX) announced that CEO Ilan Hadar will participate in the Benzinga All Access event on December 16, 2021, at 10:00 A.M. ET. The event features a live interview with Spencer Israel, Executive Producer of Benzinga TV. Investors can watch the event here. PainReform, focused on reformulating established therapeutics, aims to provide extended post-operative pain relief with its product PRF-110.
PainReform (Nasdaq: PRFX) has reported progress towards commencing Phase 3 clinical trials for PRF-110, its lead product aimed at post-operative pain relief, using ropivacaine. The company has selected Pharmaceutics International, Inc. as its U.S. manufacturer for clinical batches. They expect to start the first trial in bunionectomy by late 2022. Despite a net loss of $5.5 million for the first nine months of 2021, PainReform maintains a healthy cash balance of $18.4 million, providing a runway for important milestones ahead.
PainReform Ltd. (Nasdaq: PRFX) announced that CEO Ilan Hadar will present at the Dawson James Securities Small Cap Growth Conference on October 21, 2021, at 3:15 PM ET in Jupiter, Florida. This conference will feature one-on-one meetings with qualified investors. The live webcast and recorded presentation will be accessible on PainReform's investor relations website. PainReform specializes in reformulating therapeutics, focusing on PRF-110, which targets post-operative pain relief through an innovative drug-delivery system.
PainReform Ltd. (NASDAQ: PRFX) announced a shift of manufacturing operations for its lead product, PRF-110, to a U.S.-based Contract Development and Manufacturing Organization to enhance quality and efficiency. This decision aims to resolve previous manufacturing delays, with plans to initiate Phase 3 clinical trials by Q1 2022. As of June 30, 2021, PainReform reported $17.8 million in cash, which increased to over $19 million following recent warrant exercises. The company also reported a net loss of $3.7 million for the first half of 2021, up from $2.0 million a year earlier.
PainReform Ltd. (Nasdaq: PRFX) reported significant advancements towards launching Phase 3 clinical trials for PRF-110, targeting post-operative pain relief in bunionectomy surgery. With a strong cash position of $19.4 million as of March 31, 2021, the company is prepared for ongoing activities and future trials. Recent financial results show a net loss of $2.041 million for Q1 2021, reflecting a 57% increase from the previous year due to rising operational costs linked to clinical trial preparations. The firm remains optimistic about PRF-110's potential to reduce opioid reliance.
PainReform Ltd. (Nasdaq: PRFX) announced significant progress in its Phase 3 clinical trials for PRF-110. The company engaged Lotus Clinical Research for the bunionectomy surgery trial, set to begin mid-2021. Recent achievements include a $6 million private placement, enhancing its cash runway for key milestones. However, the company reported a net loss of $4.1 million for 2020, with substantial increases in R&D and administrative expenses. The cash position as of December 31, 2020, was $15.7 million, expected to fund operations into Q2 2022.